Activation of the receptor tyrosine kinase AXL regulates the immune microenvironment in glioblastoma

Cancer Research

Volumn 78, Issue 11, 2018, Pages 3002-3013

  Sadahiro, Hirokazu ^a,b   Kang, Kyung Don ^a   Gibson, Justin T ^c   Minata, Mutsuko ^a   Yu, Hai ^a,d   Shi, Junfeng ^e   Chhipa, Rishi ^f   Chen, Zhihong ^g   Lu, Songjian ^h   Simoni, Yannick ⁱ   Furuta, Takuya ^j   Sabit, Hemragul ^k   Zhang, Suojun ^a,l   Bastola, Soniya ^a   Yamaguchi, Shinobu ^a   Alsheikh, Hebaallah ^a   Komarova, Svetlana ^a   Wang, Jun ^a   Kim, Sung Hak ^m   Hambardzumyan, Dolores ^g   Lu, Xinghua ^h   Newell, Evan W ⁱ   DasGupta, Biplab ^f   Nakada, Mitsutoshi ^k   Lee, L James ^e   Nabors, Burt ^a   Norian, Lyse A ^c,n   Nakano, Ichiro ^a,n   more..

^a University of Alabama at Birmingham   (United States)

^b YAMAGUCHI UNIVERSITY   (Japan)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d XI'AN JIAOTONG UNIVERSITY   (China)

^e The Ohio State University   (United States)

^f CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

ⁱ NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^j KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k KANAZAWA UNIVERSITY   (Japan)

^l HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^m Chonnam National University   (South Korea)

ⁿ UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AXL PROTEIN TYROSINE KINASE; BEMCENTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NIVOLUMAB; PROTEIN S; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; FUSED ALICYCLIC AROMATIC COMPOUND; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; R428 COMPOUND; TRIAZOLE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROGLIA; MIDDLE AGED; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; APOPTOSIS; BRAIN TUMOR; CELL MOTION; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; GLIOMA; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZOCYCLOHEPTENES; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GLIOBLASTOMA; GLIOMA; HUMANS; MALE; MICE; MIDDLE AGED; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; TRIAZOLES; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85048049547     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-2433     Document Type: Article

References (45)

1. Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, et al. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Rep 2015;4:899–913.
2. Graham DK, DeRyckere D, Davies KD, Earp HS. The TAM family: phos-phatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer 2014;14:769–85.
3. Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, et al. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases. Cell 1995;80:661–70.
4. Varnum BC, Young C, Elliott G, Garcia A, Bartley TD, Fridell Y-W, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature 1995;373:623–6.
5. Ben-Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waize-negger JS, et al. Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood 2013;122:2443–52.
6. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC, Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene 2013;33: 1316–24.
7. Sheridan C. First Axl inhibitor enters clinical trials. Nat Biotechnol 2013;31:775–6.
8. Skinner HD, Giri U, Yang LP, Kumar M, Liu Y, Story MD, et al. Integrative analysis identifies a novel AXL-PI3 Kinase-PD-L1 signaling axis associated with radiation resistance in head and neck cancer. Clin Cancer Res 2017;23:2713–22.
9. Wolchok JD. PD-1 Blockers. Cell 2015;162:937.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey LC, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23–34.
11. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE, et al. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4þ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007;13:2158–67
12. Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, et al. Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model. Cancer Immunol Res 2016;4: 124–35.
13. Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Rad Oncol Biol Phys 2013;86:343–9.
14. Huang J, Liu F, Liu Z, Tang H, Wu H, Gong Q, et al. Immune checkpoint in glioblastoma: promising and challenging. Front Pharmacol 2017;8:242.
15. Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad AS, et al. Recent advances and future of immunotherapy for glioblastoma. Expert Opin Biol Ther 2016;16:1–20.
16. Preusser M, Lim M, Hafler DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. Nat Rev Neurol 2015;11:504–14.
17. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013;23: 839–52.
18. Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Rep 2015;4:226–38.
19. Mao P, Joshi K, Li J, Kim S-HH, Li P, Santana-Santos L, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Nat Acad Sci U S A 2013;110: 8644–9.
20. Alcantara Llaguno S, Chen J, Kwon C-H, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009;15:45–56.
21. Chang L, Gallego-Perez D, Zhao X, Bertani P, Yang Z, Chiang CL, et al. Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy. Lab Chip 2015;15: 3147–53.
22. Gallego-Perez D,Chang L,Shi J,Ma J,Kim SH,Zhao X, etal.On-Chipclonal analysis of glioma-stem-cell motility and therapy resistance. Nano Lett 2016;16:5326–32.
23. Simoni Y, Fehlings M, Kløverpris HN, McGovern N, Koo S-L, Loh C, et al. Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency. Immunity 2017;46:148–61.
24. Finck R, Simonds EF, Jager A, Krishnaswamy S, Sachs K, Fantl W, et al. Normalization of mass cytometry data with bead standards. Cytometry Part A 2013;83A:483–94.
25. Cheng P, Wang J, Waghmare I, Sartini S, Coviello V, Zhang Z, et al. FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cancer Res 2016;76: 7219–30.
26. Beier CP, Kumar P, Meyer K, Leukel P, Bruttel V, Aschenbrenner I, et al. The cancer stem cell subtype determines immune infiltration of glioblastoma. Stem Cells Develop 2012;21:2753–61.
27. Bhat KPLPL,Balasubramaniyan V,Vaillant B,Ezhilarasan R,Hummelink K, Hollingsworth F, et al. Mesenchymal differentiation mediated by NFkB promotes radiation resistance in glioblastoma. Cancer Cell 2013;24: 331–46.
28. Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res 2013;1:112–22.
29. Rutledge CW, Kong J, Gao J, Gutman DA, Cooper L, Appin C, et al. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. Clin Cancer Res 2013;19:4951–60.
30. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia 2012;60:502–14.
31. Chen Z, Feng X, Herting CJ, Garcia VA, Nie K, Pong WW, et al. Cellular and molecular identity of tumor-associated macrophages in glioblastoma. Cancer Res 2017;77:2266–78.
32. Kim S-HH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, et al. Serine/Threonine kinase MLK4 determines mesenchymal identity in glioma stem cells in an NFkB-dependent manner. Cancer Cell 2016; 29:201–13.
33. Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 2015;162:1217–28.
34. Reardon DA, Omuro A, Brandes AA, Rieger J, Wick A, Sepulveda J, et al. OS10.3 Randomized Phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncol 2017;19:iii21. https://doi.org/10.1093/neuonc/nox036.071.
35. Aguilera TA, Rafat M, Castellini L, Shehade H, Kariolis MS, Hui AB, et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun 2016;7:13898.
36. Hugo W, Zaretsky JM, Sun L, Song C, Moreno B, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma. Cell 2016;165:35–44.
37. Antony J, Tan T, Kelly Z, Low J, Choolani M, Recchi C, et al. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer. Sci Signal 2016;9:ra97.
38. Hutterer M, Knyazev P, Abate A, Reschke M, Maier H, Stefanova N, et al. Axl and growth arrest–specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multi-forme. Clin Cancer Res 2008;14:130–8.
39. Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Nat Acad Sci U S A 2014;111:13373–8.
40. Shiozawa Y, Pedersen EA, Patel LR, Ziegler AM. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 2010;12:116–27.
41. Abboud-Jarrous G, Priya S, Maimon A, Fischman S, Cohen-Elisha M, Czerninski R, et al. Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Oncotarget 2017;8:13986–4007.
42. Loges S, Gjertsen B, Heuser M, Ben-Batalla I, Micklem D, Jorg C, et al. A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS. J Clin Oncol 2016;34:2561. DOI: 10.1200/JCO.2016.34.15_suppl.2561.
43. Vouri M, An Q, Birt M, Pilkington GJ, Hafizi S. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Oncotarget 2015;6:16183–97.
44. Gao J, Ward JF, Pettaway CA, Shi LZ, Subudhi SK, Vence LM, et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat Med 2017;23:551–5.
45. Aguilera TA, Giaccia AJ. Molecular pathways: oncologic pathways and their role in T-cell exclusion and immune evasion—a new role for the AXL receptor tyrosine kinase. Clin Cancer Res 2017;23:2928–33.